Evidence map›Paper›PMID 38610216›Full record

ReviewHealthcare (Basel, Switzerland)2024

Tools to Guide Radiation Oncologists in the Management of DCIS.

Maria Cristina Leonardi, Maria Alessia Zerella, Matteo Lazzeroni, Nicola Fusco, Paolo Veronesi, Viviana Enrica Galimberti, Giovanni Corso, Samantha Dicuonzo, Damaris Patricia Rojas, Anna Morra and 7 more

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maria Cristina LeonardiDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Maria Alessia ZerellaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-0992-9022
Matteo LazzeroniDivision of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-2162-4002
Nicola FuscoDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.ORCID 0000-0002-9101-9131
Paolo VeronesiDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
Viviana Enrica GalimbertiDivision of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Giovanni CorsoDepartment of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.ORCID 0000-0002-9269-0146
Samantha DicuonzoDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Damaris Patricia RojasDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Anna MorraDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Marianna Alessandra GerardiDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Chiara LorubbioDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Mattia ZaffaroniDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-4655-4634
Maria Giulia VinciniDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0001-7830-3149
Roberto OrecchiaScientific Directorate, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0001-8151-3673
Francesca MagnoniDivision of Breast Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0001-9208-988X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Similar to invasive breast cancer, ductal carcinoma in situ is also going through a phase of changes not only from a technical but also a conceptual standpoint. From prescribing radiotherapy to everyone to personalized approaches, including radiotherapy omission, there is still a lack of a comprehensive framework to guide radiation oncologists in decision making. Many pieces of the puzzle are finding their place as high-quality data mature and are disseminated, but very often, the interpretation of risk factors and the perception of risk remain very highly subjective. Sharing the therapeutic choice with patients requires effective communication for an understanding of risks and benefits, facilitating an informed decision that does not increase anxiety and concerns about prognosis. The purpose of this narrative review is to summarize the current state of knowledge to highlight the tools available to radiation oncologists for managing DCIS, with an outlook on future developments.

Indexed as

breast cancerductal carcinoma in situlocal recurrencemanagementradiotherapy

Identifiers

PMID38610216
PMCPMC11011767

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.